Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Laropiprant

Generic Name: Laropiprant

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₉ClFNO_₄S

CAS Number: 571170-77-9

Unique Ingredient Identifier: G7N11T8O78

Overview

Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

Background

Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)

Phase 1

Completed

Posted: 2011/10/13

Sponsor:Merck Sharp & Dohme ...

ID:NCT01451619

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

Phase 1

Completed

Posted: 2009/11/11

Sponsor:Merck Sharp & Dohme ...

ID:NCT01012219

A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)

Phase 1

Completed

Posted: 2008/10/08

Sponsor:Merck Sharp & Dohme ...

ID:NCT00769132

A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)

Phase 1

Completed

Posted: 2008/02/20

Sponsor:Merck Sharp & Dohme ...

ID:NCT00618995

MK0524A Phase IIb Study (0524A-011)(COMPLETED)

Phase 2

Completed

Posted: 2007/09/27

Sponsor:Merck Sharp & Dohme ...

ID:NCT00536237

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy